We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals
OLMA

113 hedge funds and large institutions have $724M invested in Olema Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

237% more call options, than puts

Call options by funds: $5.25M | Put options by funds: $1.56M

105% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 21

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

24% more capital invested

Capital invested by funds: $584M → $724M (+$140M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

16% more funds holding

Funds holding: 97 → 113 (+16)

19.29% less ownership

Funds ownership: 114.44% → 95.15% (-19%)

Holders
113
Holders Change
+16
Holders Change %
+16.49%
% of All Funds
1.65%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
33
Increased
43
Reduced
21
Closed
17
Calls
$5.25M
Puts
$1.56M
Net Calls
+$3.7M
Net Calls Change
+$1.32M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.4M
3
Morgan Stanley
Morgan Stanley
New York
+$12.7M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$9.41M
5
ABG
Ally Bridge Group
New York
+$8.86M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$27.5M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$5.62M
3
Invesco
Invesco
Georgia
-$5.12M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3.18M
5
KCM
Kynam Capital Management
New Jersey
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kingdon Capital Management
New York
$4.21M +$1.21M +90,000 +43%
Marshall Wace
27
Marshall Wace
United Kingdom
$4.08M +$2.74M +203,987 +235%
Citadel Advisors
28
Citadel Advisors
Florida
$3.98M -$2.08M -154,952 -35%
SC
29
Stempoint Capital
New York
$3.95M +$3.78M +281,287 New
Ameriprise
30
Ameriprise
Minnesota
$3.65M -$1.19M -88,918 -25%
Acadian Asset Management
31
Acadian Asset Management
Massachusetts
$3.59M -$3.18M -236,956 -48%
Deutsche Bank
32
Deutsche Bank
Germany
$3.49M +$3.15M +234,143 +1,613%
HS
33
HighVista Strategies
Massachusetts
$3.48M – – –
EI
34
EAM Investors
California
$3.2M -$204K -15,151 -6%
CS
35
Candriam SCA
Luxembourg
$3.02M +$2.89M +215,008 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$2.54M -$793K -59,000 -25%
Renaissance Technologies
37
Renaissance Technologies
New York
$2.44M -$1.84M -136,889 -44%
Two Sigma Investments
38
Two Sigma Investments
New York
$2.32M +$455K +33,867 +26%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$2.13M +$1.57M +116,874 +334%
NM
40
Newtyn Management
New York
$2.1M – – –
Jacobs Levy Equity Management
41
Jacobs Levy Equity Management
New Jersey
$2.1M -$1.27M -94,813 -39%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.42M +$124K +9,235 +10%
N
43
Nuveen
North Carolina
$1.42M +$5.29K +394 +0.4%
Wellington Management Group
44
Wellington Management Group
Massachusetts
$1.39M +$3.92K +292 +0.3%
Charles Schwab
45
Charles Schwab
California
$1.25M +$124K +9,258 +12%
Millennium Management
46
Millennium Management
New York
$1.22M -$1.7M -126,842 -59%
VA
47
VR Adviser
New York
$1.08M – – –
CAM
48
ClariVest Asset Management
California
$947K +$21.1K +1,568 +2%
Swiss National Bank
49
Swiss National Bank
Switzerland
$906K +$868K +64,600 New
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$877K +$840K +62,500 New
1
2
3 4 5

OLMA Hedge Fund Activity: Q4 2023 in Review

113 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2023, worth a combined $724M — up 24% from $584M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new OLMA positions and 17 closed out — a net gain of 16 holders — while 43 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Cormorant Asset Management, cutting an estimated $27.5M.

  • 113 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2023, up from 97 in Q3 2023.
  • Funds reported $724M of Olema Pharmaceuticals stock for Q4 2023, up 24% quarter-over-quarter.
  • 33 funds opened new Olema Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +16 holders.
  • The largest Olema Pharmaceuticals buyer in Q4 2023 was BlackRock, an estimated $13.7M added.
  • The largest Olema Pharmaceuticals seller in Q4 2023 was Cormorant Asset Management, an estimated $27.5M sold.

Based on aggregated 13F filings for Q4 2023.